HRP20200444T1 - U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba - Google Patents
U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba Download PDFInfo
- Publication number
- HRP20200444T1 HRP20200444T1 HRP20200444TT HRP20200444T HRP20200444T1 HR P20200444 T1 HRP20200444 T1 HR P20200444T1 HR P20200444T T HRP20200444T T HR P20200444TT HR P20200444 T HRP20200444 T HR P20200444T HR P20200444 T1 HRP20200444 T1 HR P20200444T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- acid
- aqueous
- patient
- preparation
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 4
- 229940127291 Calcium channel antagonist Drugs 0.000 title 1
- 239000000480 calcium channel blocker Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 22
- 238000002360 preparation method Methods 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 9
- 239000000243 solution Substances 0.000 claims 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 229940098779 methanesulfonic acid Drugs 0.000 claims 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 3
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 claims 3
- 239000002552 dosage form Substances 0.000 claims 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 2
- 159000000021 acetate salts Chemical class 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 239000002738 chelating agent Substances 0.000 claims 2
- 239000003002 pH adjusting agent Substances 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 239000013011 aqueous formulation Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 238000007865 diluting Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 229950008882 polysorbate Drugs 0.000 claims 1
- 229920000136 polysorbate Polymers 0.000 claims 1
- 206010047302 ventricular tachycardia Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (15)
1. Vodeni pripravak formuliran za nazalno davanje koji sadrži farmaceutski prihvatljivu acetatnu ili metansulfonatnu sol spoja I
[image]
ili njegov racemat ili enantiomer, naznačen time što je spoj I, ili njegov racemat ili enantiomer, otopljen u vodenom pripravku u koncentraciji od između 150 mg/mL i 600 mg/mL.
2. Vodeni pripravak prema patentnom zahtjevu 1, naznačen time što spoj je S-enantiomer spoja I.
3. Vodeni pripravak prema patentnom zahtjevu 1 ili 2, naznačen time što koncentracija iznosi približno 350 mg/mL ili približno 450 mg/mL.
4. Vodeni pripravak prema bilo kojem od patentnih zahtjeva 1-3, naznačen time što vodeni pripravak sadrži od 40% do 85% (m/v) vode ili pri čemu vodeni pripravak ima pH od 4,5 ± 1,5.
5. Pripravak prema bilo kojem od patentnih zahtjeva 1-4, naznačen time što vodeni pripravak sadrži spoj I i između 0,5 i 1,5 molarnih ekvivalenata octene kiseline u odnosu na spoj ili pri čemu vodeni pripravak sadrži spoj I i između 0,5 i 1,5 molarnih ekvivalenata metansulfonske kiseline u odnosu na spoj.
6. Vodeni pripravak prema bilo kojem od patentnih zahtjeva 1-5, naznačen time što pripravak nadalje sadrži
i) kelirajuće sredstvo, naročito pri čemu kelirajuće sredstvo je aminopolikarboksilna kiselina;
ii) EDTA; i/ili
iii) sredstvo za podešavanje pH izabrano iz skupine koja se sastoji od sumporne kiseline i metansulfonske kiseline, naročito pri čemu je sredstvo za podešavanje pH sumporna kiselina.
7. Pripravak prema bilo kojem od patentnih zahtjeva 1-6, naznačen time što pripravak pokazuje viskoznost od između 10 mPa*s i 70 mPa*s.
8. Pripravak prema bilo kojem od patentnih zahtjeva 1-7, naznačen time što pripravak nadalje sadrži farmaceutski prihvatljivu pomoćnu tvar, naročito pri čemu je pomoćna tvar polisorbat ili propilen glikol.
9. Pripravak prema bilo kojem od patentnih zahtjeva 1-8, naznačen time što vodena otopina koja sadrži sol spoja I ostaje homogena na sobnoj temperaturi, ostaje homogena na 10° C tijekom 4 dana ili ostaje homogena na 2-5° C tijekom 7 dana.
10. Sustav za nazalno davanje koji sadrži pripravak prema bilo kojem od zahtjeva 1-9 u jediničnom obliku doziranja koji sadrži ne više od četiri doziranja s jednom pumpicom ili jediničnom obliku doziranja koji sadrži ne više od dva doziranja s jednom pumpicom, naročito pri čemu je jedinični oblik doziranja konfiguriran za primjenu ne više od 200 mikrolitara pripravka u svaku nosnicu pacijenta ili za primjenu ne više od 150 mikrolitara pripravka u svaku nosnicu pacijenta.
11. Pripravak naznačen time što sadrži acetatnu sol spoja I ili metansulfonatnu sol spoja I.
12. Spoj I za uporabu u postupku liječenja bolesti odabrane iz skupine koja se sastoji od srčane aritmije, stabilne angine i migrene, pri čemu navedeni postupak uključuje nazalno davanje pacijentu kojem je potrebno vodenog pripravka koji sadrži farmaceutski prihvatljivu acetatnu sol spoja I ili metansulfonatnu sol spoja I, naznačen time što je spoj I otopljen u vodenom pripravku u koncentraciji od između 150 mg/mL i 600 mg/mL.
13. Spoj I za uporabu prema patentnom zahtjevu 12,
i) pri čemu navedena srčana aritmija je PSVT, atrijska fibrilacija, ili ventrikularna tahikardija;
ii) pri čemu spoj postiže terapeutski učinkovitu koncentraciju u plazmi pacijenta u roku od 3 do 5 minuta nakon davanja pacijentu;
iii) pri čemu postupak obuhvaća davanje između 150 mikrolitara i 200 mikrolitara vodenog pripravka pacijentu; i/ili
iv) pri čemu pacijent je čovjek.
14. Postupak dobivanja otopine formulirane za nazalno davanje pacijentu, naznačen time što postupak uključuje korake
a. dodavanje otopine koja sadrži prvu otopljenu kiselinu slobodnoj bazi spoja prema patentnom zahtjevu 1 kako bi nastala smjesa, pri čemu je prva otopljena kiselina odabrana iz skupine koja se sastoji od octene kiseline i metansulfonske kiseline;
b. dodavanje u smjesu otopine koja sadrži etilendiamintetraoctenu kiselinu;
c. zagrijavanje i mehaničko miješanje dobivene smjese sve dok se spoj potpuno ne rasprši unutar smjese;
d. podešavanje pH smjese dodavanjem u smjesu otopine koja sadrži drugu otopljenu kiselinu; i
e. razrjeđivanje smjese tako da konačna koncentracija spoja u otopini iznosi najmanje 300 mg po 1 mililitru.
15. Postupak prema patentnom zahtjevu 14,
i) pri čemu je druga otopljena kiselina odabrana iz skupine koja se sastoji od octene kiseline, sumporne kiseline i metansulfonske kiseline; ili
ii) pri čemu konačni pH otopine iznosi između oko 4,0 i oko 5,0, naročito pri čemu konačni pH otopine iznosi oko 4,5; ili
iii) pri čemu otopina koja sadrži sol spoja ostaje homogena na 10° C tijekom 4 dana; ili
iv) pri čemu otopina koja sadrži sol spoja ostaje homogena na 2-5° C tijekom 7 dana.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562147427P | 2015-04-14 | 2015-04-14 | |
| PCT/CA2016/050425 WO2016165014A1 (en) | 2015-04-14 | 2016-04-13 | Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof |
| EP16779363.7A EP3283067B1 (en) | 2015-04-14 | 2016-04-13 | Highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200444T1 true HRP20200444T1 (hr) | 2020-06-12 |
Family
ID=57125495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200444TT HRP20200444T1 (hr) | 2015-04-14 | 2020-03-18 | U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba |
Country Status (28)
| Country | Link |
|---|---|
| US (10) | US10117848B2 (hr) |
| EP (2) | EP3689344B1 (hr) |
| JP (1) | JP6785792B2 (hr) |
| KR (2) | KR20240044546A (hr) |
| CN (2) | CN107613970B (hr) |
| AU (1) | AU2016249030B2 (hr) |
| BR (1) | BR112017021620B1 (hr) |
| CA (2) | CA2982622C (hr) |
| CY (1) | CY1122931T1 (hr) |
| DK (1) | DK3283067T3 (hr) |
| ES (1) | ES2778673T3 (hr) |
| HK (1) | HK1249417A1 (hr) |
| HR (1) | HRP20200444T1 (hr) |
| HU (1) | HUE049570T2 (hr) |
| IL (1) | IL254889B (hr) |
| LT (1) | LT3283067T (hr) |
| MA (2) | MA46679B1 (hr) |
| MD (1) | MD3283067T2 (hr) |
| ME (1) | ME03679B (hr) |
| MX (1) | MX2017013355A (hr) |
| PL (1) | PL3283067T3 (hr) |
| PT (1) | PT3283067T (hr) |
| RS (1) | RS60154B1 (hr) |
| RU (1) | RU2731918C2 (hr) |
| SI (1) | SI3283067T1 (hr) |
| UA (1) | UA121330C2 (hr) |
| WO (1) | WO2016165014A1 (hr) |
| ZA (2) | ZA201706648B (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230065401A1 (en) | 2021-07-15 | 2023-03-02 | Milestone Pharmaceuticals Inc. | Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6831663B2 (en) * | 2001-05-24 | 2004-12-14 | Microsoft Corporation | System and process for automatically explaining probabilistic predictions |
| US20050191245A1 (en) | 2004-02-27 | 2005-09-01 | Adams Christopher P. | Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders |
| WO2008019106A1 (en) * | 2006-08-04 | 2008-02-14 | Artesian Therapeutics, Inc. | Methods and compositions for the treatment of pulmonary hypertension using a combination of a calcium channel blocker and a phosphodiesterase inhibitor |
| WO2008156820A1 (en) | 2007-06-20 | 2008-12-24 | Milestone Pharmaceuticals Inc. | Short acting phenylalkylamine calcium channel blockers and uses thereof |
| US20090318413A1 (en) | 2008-06-18 | 2009-12-24 | Universite Victor Segalen Bordeaux 2 | Bronchial smooth muscle remodeling involves calcium-dependent enhanced mitochondrial biogenesis in asthma |
| EP2413902B1 (en) * | 2009-03-18 | 2019-07-17 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
-
2016
- 2016-04-13 MA MA46679A patent/MA46679B1/fr unknown
- 2016-04-13 MX MX2017013355A patent/MX2017013355A/es active IP Right Grant
- 2016-04-13 CA CA2982622A patent/CA2982622C/en active Active
- 2016-04-13 EP EP19218071.9A patent/EP3689344B1/en active Active
- 2016-04-13 RS RS20200312A patent/RS60154B1/sr unknown
- 2016-04-13 SI SI201630690T patent/SI3283067T1/sl unknown
- 2016-04-13 ME MEP-2020-59A patent/ME03679B/me unknown
- 2016-04-13 JP JP2017554520A patent/JP6785792B2/ja active Active
- 2016-04-13 UA UAA201711059A patent/UA121330C2/uk unknown
- 2016-04-13 US US15/566,122 patent/US10117848B2/en active Active
- 2016-04-13 CN CN201680031696.1A patent/CN107613970B/zh active Active
- 2016-04-13 BR BR112017021620-5A patent/BR112017021620B1/pt active IP Right Grant
- 2016-04-13 CA CA3203288A patent/CA3203288A1/en active Pending
- 2016-04-13 PL PL16779363T patent/PL3283067T3/pl unknown
- 2016-04-13 KR KR1020247010307A patent/KR20240044546A/ko not_active Application Discontinuation
- 2016-04-13 RU RU2017134553A patent/RU2731918C2/ru active
- 2016-04-13 AU AU2016249030A patent/AU2016249030B2/en active Active
- 2016-04-13 EP EP16779363.7A patent/EP3283067B1/en active Active
- 2016-04-13 ES ES16779363T patent/ES2778673T3/es active Active
- 2016-04-13 WO PCT/CA2016/050425 patent/WO2016165014A1/en active Application Filing
- 2016-04-13 HU HUE16779363A patent/HUE049570T2/hu unknown
- 2016-04-13 LT LTEP16779363.7T patent/LT3283067T/lt unknown
- 2016-04-13 MA MA052480A patent/MA52480A/fr unknown
- 2016-04-13 KR KR1020177031183A patent/KR102653347B1/ko active IP Right Grant
- 2016-04-13 MD MDE20180191T patent/MD3283067T2/ro unknown
- 2016-04-13 CN CN202111137477.0A patent/CN113694019A/zh active Pending
- 2016-04-13 DK DK16779363.7T patent/DK3283067T3/da active
- 2016-04-13 PT PT167793637T patent/PT3283067T/pt unknown
-
2017
- 2017-10-03 ZA ZA2017/06648A patent/ZA201706648B/en unknown
- 2017-10-03 IL IL254889A patent/IL254889B/en unknown
-
2018
- 2018-07-11 HK HK18108971.6A patent/HK1249417A1/zh unknown
- 2018-09-27 US US16/144,315 patent/US20190022048A1/en not_active Abandoned
- 2018-11-08 ZA ZA2018/07495A patent/ZA201807495B/en unknown
-
2019
- 2019-05-17 US US16/414,936 patent/US20190269643A1/en not_active Abandoned
- 2019-12-19 US US16/721,275 patent/US20200121631A1/en not_active Abandoned
-
2020
- 2020-03-18 HR HRP20200444TT patent/HRP20200444T1/hr unknown
- 2020-03-30 CY CY20201100300T patent/CY1122931T1/el unknown
- 2020-08-13 US US16/992,328 patent/US20200368195A1/en not_active Abandoned
-
2021
- 2021-03-18 US US17/205,726 patent/US20210205258A1/en not_active Abandoned
- 2021-10-26 US US17/510,968 patent/US20220040139A1/en not_active Abandoned
-
2022
- 2022-06-02 US US17/830,496 patent/US20220296556A1/en not_active Abandoned
-
2023
- 2023-01-13 US US18/154,458 patent/US20230157990A1/en not_active Abandoned
- 2023-09-06 US US18/242,766 patent/US20230414553A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2731899T3 (es) | Composición de vacuna nasal contra la gripe | |
| JP6259454B2 (ja) | ジクロフェナク製剤 | |
| BRPI0508933A (pt) | composições para entrega tópica | |
| JP2016539921A5 (hr) | ||
| US20050287220A1 (en) | Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same | |
| CN105748408A (zh) | 微乳、微乳制剂及其制备方法 | |
| HRP20200329T1 (hr) | Poboljšane formulacije levosimendana za intravensku primjenu u obliku infuzije ili injekcije i koncentrata infuzije | |
| AU2015237371A1 (en) | Stable veterinary anthelmintic formulations | |
| JP2019501861A5 (hr) | ||
| HRP20200444T1 (hr) | U vodi visoko topive soli kratko djelujućeg fenilalkilamina blokatora kalcijevih kanala i njihova uporaba | |
| JP2016517882A5 (hr) | ||
| US9468618B2 (en) | Topical pharmaceutical gel composition of diclofenac sodium | |
| US20200330436A1 (en) | Compositions and Methods for Treatment and Prevention of Pyrexia in Horses | |
| CN103505414B (zh) | 丁苯酞滴鼻剂及其制备方法 | |
| JP5324091B2 (ja) | 薬物送達のための医薬組成物及びそれを使用する症状の治療又は予防法 | |
| RU2015145451A (ru) | Препараты для местного применения, содержащие гиалуроновую кислоту, вербаскозид и глицерофосфоинозитол | |
| JP6503626B2 (ja) | 医薬組成物 | |
| CN101125145A (zh) | 局部用前列腺素微乳剂及其制备方法 | |
| CN103550150A (zh) | 改进的含二甲基硅油的注射剂 | |
| KR101690765B1 (ko) | 항진균성 활성물질을 포함하는 경피 제제 | |
| JP6704702B2 (ja) | ヨウ素系殺菌成分を含有する水性外用組成物 | |
| JP2018514527A5 (hr) | ||
| JP2009508853A (ja) | 駆虫製剤 | |
| CN108143709A (zh) | 促进第五型磷酸二酯酶抑制剂经皮吸收的方法及医药组合物 | |
| ES2608339T3 (es) | Emulsión antitumoral a base de Lipiodol para el tratamiento del cáncer |